Latest news with #Seegene
Yahoo
13-05-2025
- Business
- Yahoo
High Growth Tech Stocks in Asia for May 2025
As global markets navigate a landscape of mixed economic signals and trade negotiations, Asian tech stocks have captured investors' attention with their potential for high growth amid these uncertain times. In this environment, identifying promising tech stocks often involves looking for companies that demonstrate resilience and adaptability to evolving market conditions, such as those benefiting from technological advancements or shifts in consumer demand. Name Revenue Growth Earnings Growth Growth Rating Suzhou TFC Optical Communication 28.52% 29.12% ★★★★★★ Fositek 26.80% 33.99% ★★★★★★ Range Intelligent Computing Technology Group 28.34% 29.48% ★★★★★★ eWeLLLtd 24.66% 25.31% ★★★★★★ Nanya New Material TechnologyLtd 22.72% 63.29% ★★★★★★ ALTEOGEN 54.92% 71.24% ★★★★★★ PharmaResearch 21.74% 25.00% ★★★★★★ giftee 21.13% 67.05% ★★★★★★ HFR 33.91% 111.76% ★★★★★★ JNTC 34.26% 86.00% ★★★★★★ Click here to see the full list of 476 stocks from our Asian High Growth Tech and AI Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Seegene, Inc. is a global company specializing in the production and sale of molecular diagnostics products, with a market capitalization of ₩1.36 billion. Operations: Seegene, Inc. generates revenue primarily from the sale of diagnostic kits and equipment, totaling ₩414.25 billion. Seegene is steering the future of laboratory automation with its innovative CURECA™ system, designed to enhance efficiency in PCR testing. This system, which integrates technologies for automated sample handling and analysis, could significantly reduce human error and increase throughput in clinical labs. Despite a challenging fiscal year where Seegene reported a net loss of KRW 20.34 billion from sales of KRW 414.25 billion, the company's commitment to R&D and product innovation remains robust. The anticipated profitability over the next three years alongside a revenue growth forecast at 15.3% annually suggests Seegene is positioning itself strongly within the high-tech sector in Asia. Click here to discover the nuances of Seegene with our detailed analytical health report. Gain insights into Seegene's past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Sansan, Inc. is a Japanese company that specializes in the planning, development, and sale of cloud-based solutions, with a market capitalization of ¥257.57 billion. Operations: Sansan, Inc. generates revenue primarily from its Sansan/Bill One Business, which accounts for ¥35.69 billion, while the Eight Business contributes ¥4.73 billion. The company's focus on cloud-based solutions positions it within the tech industry in Japan. Sansan, a trailblazer in digital business card management and contact management solutions, is harnessing robust growth metrics that underscore its strategic positioning in Asia's tech landscape. With an anticipated revenue increase of 17.6% annually, the company outpaces the Japanese market average of 4%. This performance is bolstered by an aggressive R&D commitment, evident from its latest fiscal projections showing planned expenditures to enhance product capabilities and market reach. Notably, Sansan's recent corporate guidance forecasts net sales hitting between JPY 43 billion to JPY 44 billion for FY2025. The firm also shines with a projected annual earnings growth of 38.9%, significantly higher than the broader market's expectation of 7.5%, positioning it as a potent entity in technological innovation within the region. Click to explore a detailed breakdown of our findings in Sansan's health report. Understand Sansan's track record by examining our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: GMO Internet Group, Inc. offers a diverse range of Internet services globally and has a market capitalization of approximately ¥359.46 billion. Operations: The company's primary revenue streams include Internet Infrastructure, generating ¥184.91 billion, followed by the Internet Finance Business at ¥43.73 billion, and the Internet Advertising and Media Business contributing ¥34.07 billion. The Crypto Asset Business adds another significant segment with ¥9.13 billion in revenue. GMO Internet Group is demonstrating a keen ability to navigate the tech sector's demands, evidenced by its robust earnings growth forecast of 16.2% annually, surpassing Japan's market average of 7.5%. This growth trajectory is supported by strategic share repurchases, with the company recently buying back 1.81% of its shares for ¥5.76 billion, underscoring confidence in its financial health and future prospects. Despite a challenging past year with earnings contraction by 5.8%, GMO continues to invest in innovation, as seen in its commitment to R&D which remains integral to overcoming industry hurdles and maintaining competitive advantage in Asia's dynamic tech landscape. Get an in-depth perspective on GMO internet group's performance by reading our health report here. Review our historical performance report to gain insights into GMO internet group's's past performance. Investigate our full lineup of 476 Asian High Growth Tech and AI Stocks right here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A096530 TSE:4443 and TSE:9449. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Asian Value Stocks Priced Below Estimated Intrinsic Worth
Amid ongoing trade discussions between major economies and recent policy shifts, Asian markets have shown resilience with notable gains in key indices. In this environment of cautious optimism, identifying value stocks priced below their estimated intrinsic worth can be a strategic approach for investors seeking to capitalize on potential market inefficiencies. Name Current Price Fair Value (Est) Discount (Est) Aidma Holdings (TSE:7373) ¥1893.00 ¥3727.32 49.2% Shenzhen KSTAR Science and Technology (SZSE:002518) CN¥23.12 CN¥45.45 49.1% Alexander Marine (TWSE:8478) NT$148.50 NT$291.28 49% Lingbao Gold Group (SEHK:3330) HK$9.44 HK$18.21 48.1% Newborn Town (SEHK:9911) HK$8.39 HK$16.46 49% GEM (SZSE:002340) CN¥6.21 CN¥12.14 48.8% World Fitness Services (TWSE:2762) NT$82.70 NT$164.43 49.7% Seegene (KOSDAQ:A096530) ₩27250.00 ₩52999.15 48.6% Bloks Group (SEHK:325) HK$129.60 HK$255.66 49.3% BrightGene Bio-Medical Technology (SHSE:688166) CN¥50.36 CN¥98.57 48.9% Click here to see the full list of 269 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. We're going to check out a few of the best picks from our screener tool. Overview: Samsung Heavy Industries Co., Ltd. operates globally in shipbuilding, offshore, and energy infrastructure sectors with a market cap of ₩12.68 trillion. Operations: The company's revenue is primarily derived from its Joseon Maritime segment at ₩9.31 trillion and its Construction segment at ₩791.65 billion. Estimated Discount To Fair Value: 27.4% Samsung Heavy Industries is trading at ₩14,840, significantly below its estimated fair value of ₩20,432.38. Analysts agree the stock price could rise by 20.2%. The company recently turned profitable with net income of KRW 63.88 billion for 2024, compared to a loss the previous year. Earnings are expected to grow significantly at over 51% annually, outpacing the Korean market's growth rate of 21.1%, despite interest payments not being well covered by earnings. Our growth report here indicates Samsung Heavy Industries may be poised for an improving outlook. Unlock comprehensive insights into our analysis of Samsung Heavy Industries stock in this financial health report. Overview: HD-Hyundai Marine Engine Co., Ltd. manufactures and sells marine engines, industrial facilities, and plants both in South Korea and internationally, with a market cap of ₩1.39 trillion. Operations: The company's revenue is primarily derived from its Engine and Equipment segment, which generated ₩315.79 billion. Estimated Discount To Fair Value: 33.5% HD-Hyundai Marine Engine's earnings surged to KRW 75.78 billion in 2024 from KRW 31.64 billion the previous year, with revenue forecasted to expand at a rapid pace of 27.2% annually, outstripping market growth. Despite recent shareholder dilution and high share price volatility, the stock trades at ₩40,850—33.5% below its estimated fair value of ₩61,451.66—highlighting its potential as an undervalued investment based on cash flows despite large one-off items impacting results. According our earnings growth report, there's an indication that HD-Hyundai Marine Engine might be ready to expand. Click to explore a detailed breakdown of our findings in HD-Hyundai Marine Engine's balance sheet health report. Overview: TORIDOLL Holdings Corporation operates and manages restaurants both in Japan and internationally, with a market cap of ¥387.74 billion. Operations: The company's revenue segments include Marugame Seimen generating ¥125.38 billion and the Overseas Business contributing ¥102.43 billion. Estimated Discount To Fair Value: 42.8% TORIDOLL Holdings is trading at ¥4,426, significantly below its estimated fair value of ¥7,739.11. Earnings are projected to grow 35.3% annually, surpassing the JP market's 7.6% growth rate, while revenue is expected to increase by 8.5% per year. However, a low forecasted return on equity of 11.3% and the impact of large one-off items on financial results may temper enthusiasm for this undervalued stock based on cash flows. The growth report we've compiled suggests that TORIDOLL Holdings' future prospects could be on the up. Take a closer look at TORIDOLL Holdings' balance sheet health here in our report. Investigate our full lineup of 269 Undervalued Asian Stocks Based On Cash Flows right here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A010140 KOSE:A071970 and TSE:3397. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
07-05-2025
- Business
- Yahoo
In Vitro Diagnostics Market Size to be Worth $150.13 Billion by 2030 at CAGR 5.62%
SAN FRANCISCO, May 7, 2025 /PRNewswire/ -- The global in vitro diagnostics market size is expected to reach USD 150.13 billion in 2030 and is projected to grow at a CAGR of 5.62% from 2025 to 2030. driven by the increasing geriatric population, COVID-19 pandemic, and technological advancements in diagnostics that are supporting its adoption. Technological advancements in terms of portability, accuracy, and cost-effectiveness are projected to be one of the high-impact rendering drivers. Technological advancements were further accelerated by the launch of COVID-19 IVD diagnostics and enhanced the adoption of instruments and consumables for technologies, such as PCR. Competitors in the market are increasingly adopting agreement and partnership strategies to maintain a constant flow of business for manufacturers & diagnostics for users. Grand_View_Research_Logo These agreements are also a result of the harsh price containment strategies for government laboratories, which lowers the price in government settings. For instance, in April 2021, the Italian subsidiary of Seegene, Inc. received a USD 108.25 million tenders for public procurement for the supply of extraction reagents, as well as 7.15 million SARS-CoV-2 diagnostic tests. However, it increases the multiparty nature and complexity of the supply chain. The high prevalence of cancer and Cardiovascular Diseases (CVDs) globally is anticipated to drive diagnostic innovation to facilitate early diagnosis and meet the constantly evolving needs of consumers. Novel technologies, such as plasmonic PCR, are anticipated to commercially enter the market during the forecast period, influencing the business of existing products adversely. Request a free sample copy or view report summary: In Vitro Diagnostics Market In Vitro Diagnostics Market Report Highlights:
Korea Herald
03-05-2025
- Business
- Korea Herald
Seegene's CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation
SEOUL, South Korea, May 2, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, has attracted strong interest after the company presented a conceptual video of its CURECA TM at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria. Industry professionals recognized CURECA TM as a promising advancement in automating the entire PCR diagnostic workflow — from primary sample handling to result analysis. In response to the interest received, Seegene provided additional opportunities to showcase the solution at the ESCMID Global 2025. More than 2,300 attendees — including dignitaries from Italy, Spain, Germany, France, and Canada — visited Seegene's booth to view the conceptual video introducing the CURECA TM. "It was evident that the Seegene booth attracted considerable attention at ESCMID," said one professional from academia. Experts Recognize CURECA TM as a Game Changer in Molecular Testing Automation The CURECA TM is designed to automate the entire PCR diagnostic process. It can handle various specimen types required in the pre-treatment stage in MDx – such as stool, urine, blood, and sputum—as well as perform the complete PCR testing workflow following sample loading. The following are select comments from industry professionals who previewed Seegene's CURECA TM at ESCMID Global 2025: "I hold high expectations for the fully automated PCR molecular diagnostics, as CURECA TM not only eliminates human error inherent in manual processes but also enables efficient testing without time or workforce constraints." "We often encounter specimen types that require careful and time-consuming manual pre-processing. A system that can automate this step could represent a true paradigm shift. This level of automation is transformative – a real game changer – and unlike any existing solution. I eagerly await its launch." "If paired with our in-house diagnostic tool kits, CURECA TM could offer a complete synergy. I hope CURECA TM will be accessible to small and mid-sized facilities." "I'm planning to attend ADLM 2025 in Chicago in July to see the actual device and explore potential collaborations." Customizable Pre-Treatment System Offers Versatility for Future Laboratory Automation The first component of CURECA TM is the Customizable Pre-treatment System (CPS). The CPS is designed to automate the loading of primary sample tubes and operate pre-treatment processing. "The CPS is a modular, automated system intended to streamline pre-treatment processing across diverse diagnostic fields including molecular diagnostics such as PCR, as well as clinical chemistry and immunology assays," said Young-Seag Baeg, Head of Strategy and Planning at Seegene. Numerous healthcare (or laboratory) professionals at ESCMID Global 2025 noted that the conceptual video of CURECA TM showcased the potential of fully automated diagnostic laboratories capable of managing complex workflows associated with pre-treatment. In particular, there was consensus among participants that the CPS, which automates specimen preprocessing, is positioned to bring a significant advancement in in vitro diagnostics as it addresses limitations associated with existing manual procedures that are dependent on trained laboratory professionals. "The turnaround time (TAT) is expected to improve with CURECA TM as the integrated software is capable of adjusting workflows based on reporting deadlines," said a director of a laboratory in Spain. "In particular, for sexually transmitted infections (STIs), the CPS will markedly enhance daily laboratory operations. The processing of specimens for STIs involves manual handling of multiple sample tubes, which contributes to operator fatigue. The adoption of the CPS has the potential to be transformational in streamlining routine operations." Modular and Configurable Solution Design for Tailored Diagnostics Following specimen preprocessing, molecular diagnostics typically involve nucleic acid extraction, PCR setup and amplification, and analysis of results. For specimens that do not need preprocessing, Seegene offers the Primary Sample Aliquot System (PAS) as an alternative to the CPS. PAS is designed to allow direct loading and dispensing of primary samples, helping to simplify the workflow. Seegene is pursuing the integration of PAS with a fully automated PCR process through a modular solution concept called CEFA (Customizable & Expandable Full Automation), intended to support diverse laboratory needs with greater flexibility. Seegene aims to leverage the modular architecture of CURECA TM to support a wide range of diagnostic applications. "CURECA TM can be deployed as a comprehensive system or as individual modules—CPS, PAS, and CEFA—configured independently or in combination to accommodate diverse operational needs," said Baeg. Optimizing Lab Workflows Through Space-Saving Design Another key advantage of the CURECA TM 's modular architecture is that it is designed to adapt to different laboratory spaces and layouts. Its flexible design is intended to allow labs to configure the system according to their specific needs, which Seegene sees as essential for enhancing operational efficiency. Laboratory professionals at ESCMID 2025 shared the following perspectives: "The ability to configure a system to meet specific spatial and operational needs of individual laboratories represents a novel and highly compelling approach." "We expect such flexibility will make it possible to implement workflows that deliver high-quality results with minimal reliance on standardized laboratory configurations and staffing resources." "The enthusiastic global response to our concept video and vision for CURECA TM demonstrate the strong demand for next-generation diagnostic solutions," said Jong-Yoon Chun, CEO of Seegene. "We believe CURECA TM has the potential to catalyze meaningful change in the global PCR diagnostics landscape." Please Note: The comments included in this press release are based on actual interviews and on-site discussions. However, in accordance with requests to protect the privacy of the individuals interviewed, all names have been pseudonimized. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information. Technology-sharing Initiative The technology-sharing initiative aims to globally share Seegene's advanced diagnostic and data analysis technologies, including syndromic real-time PCR and an automated product development system (SGDDS), with a leading company partnered in each country. Partnering companies will collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their communities and fields, spanning a wide range of human and non-human diseases. The initiative's ultimate vision is to create "a world free from diseases"—a future where people no longer suffer from infectious diseases and cancer, and where animals and plants thrive without illness.
Cision Canada
02-05-2025
- Business
- Cision Canada
Seegene's CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation
Seegene previews a concept video of CURECA TM at ESCMID Global 2025, ahead of its anticipated debut in July With a fully modular design, CURECA TM introduces a bold vision for automating pre-treatment across diverse PCR specimen types Developed for future integration into unattended workflows and adaptable laboratory settings SEOUL, South Korea, May 2, 2025 /CNW/ -- Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, has attracted strong interest after the company presented a conceptual video of its CURECA TM at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria. Industry professionals recognized CURECA TM as a promising advancement in automating the entire PCR diagnostic workflow — from primary sample handling to result analysis. In response to the interest received, Seegene provided additional opportunities to showcase the solution at the ESCMID Global 2025. More than 2,300 attendees — including dignitaries from Italy, Spain, Germany, France, and Canada — visited Seegene's booth to view the conceptual video introducing the CURECA TM. "It was evident that the Seegene booth attracted considerable attention at ESCMID," said one professional from academia. Experts Recognize CURECA TM as a Game Changer in Molecular Testing Automation The CURECA TM is designed to automate the entire PCR diagnostic process. It can handle various specimen types required in the pre-treatment stage in MDx – such as stool, urine, blood, and sputum—as well as perform the complete PCR testing workflow following sample loading. The following are select comments from industry professionals who previewed Seegene's CURECA TM at ESCMID Global 2025: "I hold high expectations for the fully automated PCR molecular diagnostics, as CURECA TM not only eliminates human error inherent in manual processes but also enables efficient testing without time or workforce constraints." "We often encounter specimen types that require careful and time-consuming manual pre-processing. A system that can automate this step could represent a true paradigm shift. This level of automation is transformative – a real game changer – and unlike any existing solution. I eagerly await its launch." "If paired with our in-house diagnostic tool kits, CURECA TM could offer a complete synergy. I hope CURECA TM will be accessible to small and mid-sized facilities." "I'm planning to attend ADLM 2025 in Chicago in July to see the actual device and explore potential collaborations." Customizable Pre-Treatment System Offers Versatility for Future Laboratory Automation The first component of CURECA TM is the Customizable Pre-treatment System (CPS). The CPS is designed to automate the loading of primary sample tubes and operate pre-treatment processing. "The CPS is a modular, automated system intended to streamline pre-treatment processing across diverse diagnostic fields including molecular diagnostics such as PCR, as well as clinical chemistry and immunology assays," said Young-Seag Baeg, Head of Strategy and Planning at Seegene. Numerous healthcare (or laboratory) professionals at ESCMID Global 2025 noted that the conceptual video of CURECA TM showcased the potential of fully automated diagnostic laboratories capable of managing complex workflows associated with pre-treatment. In particular, there was consensus among participants that the CPS, which automates specimen preprocessing, is positioned to bring a significant advancement in in vitro diagnostics as it addresses limitations associated with existing manual procedures that are dependent on trained laboratory professionals. "The turnaround time (TAT) is expected to improve with CURECA TM as the integrated software is capable of adjusting workflows based on reporting deadlines," said a director of a laboratory in Spain. "In particular, for sexually transmitted infections (STIs), the CPS will markedly enhance daily laboratory operations. The processing of specimens for STIs involves manual handling of multiple sample tubes, which contributes to operator fatigue. The adoption of the CPS has the potential to be transformational in streamlining routine operations." Modular and Configurable Solution Design for Tailored Diagnostics Following specimen preprocessing, molecular diagnostics typically involve nucleic acid extraction, PCR setup and amplification, and analysis of results. For specimens that do not need preprocessing, Seegene offers the Primary Sample Aliquot System (PAS) as an alternative to the CPS. PAS is designed to allow direct loading and dispensing of primary samples, helping to simplify the workflow. Seegene is pursuing the integration of PAS with a fully automated PCR process through a modular solution concept called CEFA (Customizable & Expandable Full Automation), intended to support diverse laboratory needs with greater flexibility. Seegene aims to leverage the modular architecture of CURECA TM to support a wide range of diagnostic applications. "CURECA TM can be deployed as a comprehensive system or as individual modules—CPS, PAS, and CEFA—configured independently or in combination to accommodate diverse operational needs," said Baeg. Optimizing Lab Workflows Through Space-Saving Design Another key advantage of the CURECA TM 's modular architecture is that it is designed to adapt to different laboratory spaces and layouts. Its flexible design is intended to allow labs to configure the system according to their specific needs, which Seegene sees as essential for enhancing operational efficiency. Laboratory professionals at ESCMID 2025 shared the following perspectives: "The ability to configure a system to meet specific spatial and operational needs of individual laboratories represents a novel and highly compelling approach." "We expect such flexibility will make it possible to implement workflows that deliver high-quality results with minimal reliance on standardized laboratory configurations and staffing resources." "The enthusiastic global response to our concept video and vision for CURECA TM demonstrate the strong demand for next-generation diagnostic solutions," said Jong-Yoon Chun, CEO of Seegene. "We believe CURECA TM has the potential to catalyze meaningful change in the global PCR diagnostics landscape." Please Note: The comments included in this press release are based on actual interviews and on-site discussions. However, in accordance with requests to protect the privacy of the individuals interviewed, all names have been pseudonimized. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information. Technology-sharing Initiative The technology-sharing initiative aims to globally share Seegene's advanced diagnostic and data analysis technologies, including syndromic real-time PCR and an automated product development system (SGDDS), with a leading company partnered in each country. Partnering companies will collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their communities and fields, spanning a wide range of human and non-human diseases. The initiative's ultimate vision is to create "a world free from diseases"—a future where people no longer suffer from infectious diseases and cancer, and where animals and plants thrive without illness. SOURCE Seegene Inc.
